ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 142 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,609,363 | +673.8% | 144,079 | +1382.4% | 0.00% | – |
| Q2 2023 | $207,987 | -74.5% | 9,719 | -51.9% | 0.00% | – |
| Q1 2023 | $816,322 | +245.9% | 20,186 | +539.4% | 0.00% | – |
| Q4 2021 | $236,000 | -62.6% | 3,157 | -71.6% | 0.00% | – |
| Q3 2021 | $631,000 | +58.1% | 11,100 | +22.5% | 0.00% | – |
| Q2 2021 | $399,000 | +99.5% | 9,060 | +90.6% | 0.00% | – |
| Q4 2020 | $200,000 | -24.2% | 4,753 | -17.6% | 0.00% | – |
| Q3 2020 | $264,000 | +26.9% | 5,767 | +39.5% | 0.00% | – |
| Q2 2020 | $208,000 | -30.2% | 4,135 | -14.3% | 0.00% | – |
| Q4 2019 | $298,000 | -15.6% | 4,826 | -17.9% | 0.00% | -100.0% |
| Q3 2019 | $353,000 | +69.7% | 5,880 | +138.8% | 0.00% | – |
| Q2 2019 | $208,000 | -45.3% | 2,462 | -54.1% | 0.00% | -100.0% |
| Q4 2018 | $380,000 | -63.6% | 5,364 | -40.4% | 0.00% | -50.0% |
| Q2 2018 | $1,043,000 | +340.1% | 9,000 | +50.5% | 0.00% | 0.0% |
| Q3 2014 | $237,000 | -49.3% | 5,981 | -44.9% | 0.00% | -66.7% |
| Q2 2014 | $467,000 | – | 10,851 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
| GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
| ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
| Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
| Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
| Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
| 361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
| ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
| AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |